E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
alcohol withdrawal and craving. |
|
E.1.1.1 | Medical condition in easily understood language |
alcohol withdrawal and craving. |
|
E.1.1.2 | Therapeutic area | Not possible to specify |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary aim of the study is to test whether daily intranasal administration of oxytocin is more effective than placebo in decreasing the oxazepam dosages required to control withdrawal symptoms during a 3-day inpatient program of medical detoxification. |
|
E.2.2 | Secondary objectives of the trial |
The secondary aims are: 1) test whether daily intranasal administration of oxytocin is more effective than placebo in decreasing CIWA-Ar scores during the detoxification period; 2) test the effects on therapist- and self-reported withdrawal symptoms, dysphoria and Actigraph-assessed akathisia and sleep during the detoxification period; and 3) test whether daily intranasal self-administration of oxytocin is more effective than placebo on alcohol use measures (time to ‘relapse’ and amount, cravings), quality of sleep and mood states during a subsequent 4 week out-patient follow-up period. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) At least one prior episode 2 days or longer in duration during which the subject experienced withdrawal symptoms that caused significant incapacitation (e.g., inability to work or do normal activities) OR at least one prior inpatient or outpatient medical detoxification during which the subject exhibited withdrawal symptoms of sufficient magnitude that sedative-hypnotic or anticonvulsant medication was required at least once on 2 consecutive days after cessation of or reduction in the use of alcohol following 2 weeks or more of heavy daily consumption; 2) average consumption of 8-30 standard drinks per day for at least 2 weeks prior to enrollment in the study; 3) age 18-65; 4) consenting to participate in the study; 5) have residency in Sør-Trøndelag County after discharge |
|
E.4 | Principal exclusion criteria |
1) chronic treatment with sedative-hypnotic medications such as benzodiazepines or z-hypnotics; 2) dependence on substances other than alcohol, nicotine or caffeine; 3) inadequately treated, unstable and/or compromising medical or psychiatric conditions; 4) low body weight (BMI < 17) or history of anorexia nervosa or bulimia in the past 2 years; 5) pregnancy; parturition or breast-feeding in the past 6 months; 6) inability to read well enough to complete study questionnaires determined by whether the prospective subject can read the consent form without help and correctly answer basic questions about information in the consent form. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint: Phase 1: Milligrams of oxazepam used to complete 3 days of detoxification. Phase 2: Time to ‘relapse’ and amount during 4 weeks of subsequent outpatient treatment.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Phase 1: at the end of the three-day in-patient stay.
Phase 2: after 4 weeks of outpatient treatment. |
|
E.5.2 | Secondary end point(s) |
Phase 1: CIWA-Ar-score, effects on mood, craving, sleep
Phase 2: Effects on therapist- and self-reported withdrawal symptoms, dysphoria and Actigraph-assessed akathisia and sleep. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Phase 1: at the end of the three-day in-patient stay.
Phase 2: after 4 weeks of outpatient treatment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |